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ABSTRACT
Prostate cancer (PCa) is known to develop resistance to chemotherapy. Growth arrest-specific 6 (GAS6), plays a role in tumor progression by
regulating growth in many cancers. Here, we explored how GAS6 regulates the cell cycle and apoptosis of PCa cells in response to
chemotherapy. We found that GAS6 is sufficient to significantly increase the fraction of cells in G1 and the duration of phase in PCa cells.
Importantly, the effect of GAS6 on G1 is potentiated during docetaxel chemotherapy. GAS6 altered the levels of several key cell cycle
regulators, including the downregulation of Cyclin B1 (G2/M phase), CDC25A, Cyclin E1, and CDK2 (S phase entry), while the cell cycle
inhibitors p27 and p21, Cyclin D1, and CDK4. Importantly, these changes became further accentuated during docetaxel treatment in the
presence of GAS6. Moreover, GAS6 alters the apoptotic response of PCa cells during docetaxel chemotherapy. Docetaxel induced PCa cell
apoptosis is efficiently suppressed. In PCa cell cultures in the presence of GAS6 or GAS6 secreted from co-cultured osteoblasts. Similarly,
the GAS6-expressing bone environment protects PCa cells from apoptosis within primary tumors in vivo studies. Docetaxel induced
significant levels of Caspase-3 and PARP cleavage in PCa cells, while GAS6 protected PCa cells from docetaxel-induced apoptotic signaling.
Together, these data suggest that GAS6, expressed by osteoblasts in the bone marrow, plays a significant role in the regulation of PCa cell
survival during chemotherapy, which will have important implications for targeting metastatic disease. J. Cell. Biochem. 117: 2815–2824,
2016. © 2016 Wiley Periodicals, Inc.
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Prostate cancer (PCa) is the second leading cause of cancerdeaths in American males [Pienta and Esper, 1993]. Death
of most PCa patients is associated with bone metastasis
[Koutsilieris, 1993]. PCa cells are known to develop resistance
to chemotherapy, particularly within the marrow [Petrioli et al.,
2003; Taichman et al., 2007; Sweeney et al., 2015]. Therefore,
understanding the mechanisms of tumor cell survival and
drug-resistance in the marrow is a key component in targeting
cancer cells more effectively.
The homing and lodging of disseminated tumor cells (DTCs) in the
bonemarrow and the survival of these cells in this microenvironment
are essential steps to establish PCa bonemetastases [Jung et al., 2015].
Recent studies suggest that many hematopoietic and mesenchymal
cells participate in the cellular and molecular events required for the
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establishment ofmetastases andmaintenance of tumor progression in
marrow [Taichman et al., 2002; Kucia et al., 2005; Sun et al., 2005;
Shiozawa et al., 2011; Jung et al., 2013]. Once in themarrow, DTC fate
includingG0–G1 cell cyclearrest ordormancyand reactivationmaybe
governed by the signals from the metastatic microenvironment. As
conventional cancer therapeutics largely target proliferating cells,
dormant DTCs may be innately protected from chemotherapeutic
insults setting the stage for subsequent relapse [Quesnel, 2008;
Yumoto et al., 2014]. Previously, we demonstrated that growth arrest-
specific 6 (GAS6) secreted by osteoblasts inhibits PCa proliferation
[Shiozawa et al., 2010].
These data suggest that once the DTCs enter an environment where
GAS6 levels are high, interactions betweenGAS6 and its receptorsmay
regulate PCa dormancy [Shiozawa et al., 2010]. Consistent with these
observations, we reported that GAS6 levels are significantly higher in
the femur and tibia versus thehumeri of SCIDmice corresponding to the
prevalence atwhichmetastatic PCa lesionsoccur following intravenous
inoculation [Junget al., 2012].Wealsodemonstrated that thebindingof
PCa cells to osteoblasts in bonemarrow induces TANKbinding kinase 1
(TBK1) expression, which induces cell cycle arrest and the enhances
chemotherapeutic resistance of PCa cells [Kim et al., 2013]. These
findings suggest that identifying novel dormancy-associated pathways
are crucial to prevent PCa recurrence and provide a more effective
therapeutic strategy for PCa.
Chemotherapy using docetaxel is a standard treatment option for
patients with metastatic castration-resistant prostate cancer. More
recently, docetaxel has also shown an impressive survival benefit
when given soon after diagnosis of metastatic hormone-sensitive
prostate cancer [Sweeney et al., 2015]. However, all patients
eventually develop chemotherapy resistance, which reduces survival
in patients with advanced prostate cancer [Hong, 2002; Sweeney
et al., 2015]. Docetaxel functions in part by disrupting the
microtubule network in cells, which is essential for cell division
during mitosis [Yoo et al., 2002; Li et al., 2004]. In addition,
docetaxel alters protein targets involved in cell survival, normal
physiological functions, and oncogenesis [Li et al., 2004]. Docetaxel
also increases cytokine production in PCa cell cultures and
circulating cytokines in castration-resistant PCa patients [Mahon
et al., 2015]. CXCL12/CXCR4 signaling is known to prevent
docetaxel-induced microtubule stabilization via p21-activated
kinase 4 (PAK4)-dependent activation of LIM domain kinase 1 in
PCa cells [Bhardwaj et al., 2014]. Further, the inflammatory cytokine
CCL2 enhances the development of resistance to docetaxel-induced
cytotoxicity in PCa cells [Qian et al., 2010; Puhr et al., 2014].
Docetaxel promotes the upregulation of the cell cycle inhibitor (p19)
and downregulation of cyclins (cyclin A and cyclin B1) in head and
neck cancer cells [Yoo et al., 2002] and results have been observed in
PCa cells with the upregulation of cyclin-dependent protein kinase
(CDK) inhibitors (p21 and p27) and downregulation of cyclins (cyclin
A2, cyclin E2, and cyclin F), CDK4, and other key cell regulators
(CDC2, CDC7, CDC20, and CDC25B) [Li et al., 2004]. Thus,
understanding the mechanisms underlying the extrinsic or intrinsic
cellular signaling process responsible for docetaxel resistance is
urgently needed.
In the present study, we explored how GAS6, expressed by
osteoblasts, regulates the cell cycle and apoptosis in PCa cells during
chemotherapy in the bone marrow. We demonstrate that GAS6
significantly increases the number of G1 arrested cells by altering
signaling networks associated with G1 arrest and S phase delay.
Furthermore, we demonstrate that GAS6 contributes to the
protection of PCa cells from docetaxel-induced apoptosis in cell
culture and similarly the GAS6-expressing bone environment
protects PCa cells from apoptosis within primary tumors in vivo
studies. In addition, we show that GAS6 can protect PCa cells from
apoptotic signaling via Caspase-3 and PARP cleavage. Our results
suggest that GAS6 contributes to the regulation of PCa cell survival
during chemotherapy in the bone marrow microenvironment.
MATERIALS AND METHODS
CELL CULTURE
Human PCa cell lines (PC3, DU145) were obtained from theAmerican
Type Culture Collection (Rockville, MD). GFP expressing PCa cell
lines (PC3GFP and DU145GFP) were established by lentiviral
transduction. Murine osteoblast cells were established as previously
reported [Jung et al., 2011]. All prostate cancer cell lines were
routinely grown in RPMI 1640 (Life Technologies, Carlsbad, CA), and
murine osteoblast cells were grown in a-MEM (Life Technologies)
supplemented with 10% fetal bovine serum (FBS, GEMINI
Bio-Products, Sacramento, CA), 1% penicillin-streptomycin (P/S,
Life Technologies) and maintained at 37°C, 5% CO2, and 100%
humidity.
PROLIFERATION ASSAY
PCa cells (PC3 or DU145) (3 103) were seeded onto 96-well culture
plates with RPMI 1640, 1% FBS, and 1% P/S and then the cells were
treated with human recombinant GAS6 (0–3mg/ml, cat.
885-GSB-050, R&D Systems, Minneapolis, MN) for 3 days.
Proliferation was measured by the XTT Assay kit (cat. TOX2, Sigma,
St. Louis, MO).
FUCCI-PC3 CELLS
To develop amethod tomonitor the cell cycle in prostate cancer cells,
we transduced a human prostate cancer cell line, PC3 with
lentiviruses containing the fluorescent ubiquitination-based cell
cycle indicator (Fucci) vectors (Clontech, Mountain View, CA). Cells
contain both a chromatin licensing and DNA replication factor 1
(CDT1)-Cherry reporter and a Geminin-Cyan reporter. Early S phase
cells are double-positive for the reporters, fluorescing yellow. M
phase is colorless due to the destruction of both Geminin-Cyan and
CDT1-Cherry [Sakaue-Sawano et al., 2008]. pRetroX-G1-Red vector
(cat. 631463, Clontech) and pRetroX-SG2M-Cyan vector
(cat. 631462, Clontech) were packaged into lentivirus at the
University of Michigan Vector Core Facility. Lentiviral
pRetroX-G1-Red vector and lentiviral pRetroX-SG2M-Cyan vector
were coinfected into PC3 cells. Infected cells were selected for 7 days
in media containing 1mg/ml Puromycin and analyzed by FACS
analysis. Cell cycle monitoring was performed in Fucci-PCa cell
culture with direct GAS6 (1–2mg/ml) treatment or with the
co-culture of osteoblasts (wild-type OB (GAS6þ/þ OB) or GAS6
deficient OB (GAS6/ OB)) following treatment with anticancer
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drug, docetaxel (Taxotere, 1mg/ml, cat. NDC0409-0201-10, Hospira,
Lake Forest, IL). Additionally, Fucci-PC3 cell imaging was captured
by video. Fucci-PC3 cells were cultured for 24 h in RPMI with 10%
FBS, 1% P/S and then, treated with Vehicle or GAS6 (2mg/ml) for
24 h. Five spots of cells in each group were set for tracking. Video
images were taken for 24 h at 15min intervals using a Deltavision
Elite Microscope (GE Healthcare Life Science, Pittsburgh, PA). The
duration of G1 phase in single cells was measured (n¼ 20/group).
CELL DEATH ASSAYS
Cell death assays were performed in PCa cell cultures treated with
GAS6 or in coculture of PCa cells with osteoblasts. First, PCa cells
(1 105 cells/well) were seeded onto 12-well culture plates for 24 h.
Cells were cultured for 24–48 h following GAS6 (2mg/ml) treatment,
and then treated with the docetaxcel (1mg/ml) for 24 h. For the
cocultures, GAS6þ/þ OB or GAS6/ OB (1 105 cells/well) was
seeded onto 12-well culture plates for 24 h. Thereafter, GFP
expressing PCa cells (1 105 cells/well) were added to the wells.
Cells were cultured together for 48 h, and then treated with the
anticancer drug, docetaxcel (1mg/ml), for 24 h in the coculture
system. Apoptosis was measured by flow cytometry (FACSAria IIu
three laser flow-cytometer, Becton Dickinson, Mountainview, CA)
using by selecting PCa cells with the GFP reporter and with the PE
Annexin V Apoptosis Detection Kit I (cat. 559763, BD Biosciences,
San Jose, CA). Assays were performed in triplicate and the results are
representative of three independent experiments. In tumor sections
from PCa cells were injected into vertebral bodies (vossicles) from
wild-type (GAS6þ/þ) or GAS6 knockout (GAS6/) mice as
described previously [Jung et al., 2011], apoptosis of PCa cells was
measured by Cell Meter TUNELApoptosis Assay Kit (cat. 22844, AAT
Bioquest, Sunnyvale, CA).
QUANTITATIVE RT-PCR
Total RNA was extracted from cells using the RNeasy mini or micro
kit (Qiagen, Valencia, CA) and converted into cDNA using a First-
Strand Synthesis Kit (Invitrogen). Quantitative PCR was performed
on an ABI 7700 sequence detector (Applied Biosystems) using
TaqMan Universal PCR Master Mix Kit (Applied Biosystems)
according to the directions of manufacturer. TaqMan MGB probes,
PLK1 (Hs00153444_m1) and STK15 (Hs01582072_m1) (Applied
Biosystems) were used. b-actin (Hs01060665-g1) was used as an
internal control for normalization of target gene expression.
ELISA
An antibody sandwich ELISA was used to evaluate GAS6 expression
in bone marrow from GAS6þ/þ or GAS6/ mice as a negative
control by following the directions of the manufacturer (cat. DY986;
R&D Systems). Bone marrow extracellular fluids were obtained by
flushing femora, and tibiae with 500ml of ice-cold PBS, and the
supernatant was harvested by centrifugation at 400g for 5min.
GAS6 levels were normalized to total protein.
IMMUNOSTAINING
Cells, tumor sections, and long bone sections were used for
immunostaining. Cells were fixed and permeabilized with Perm/
Wash Buffer (cat. 554723, BD Biosciences). Tumor sections were
blocked with Image-iT FX signal enhancer for 30min and incubated
for 2 h at room temperature with primary antibodies combined with
reagents of Zenon Alexa Fluor 488 (green) or 555 (red) labeling kit
(Invitrogen). GAS6 (cat. AF885, R&D System) antibody was used as
primary antibody. After washing with PBS, the slides were mounted
with ProLong Gold antifade reagent with DAPI (Invitrogen). Images
were taken with Olympus FV-500 confocal microscope.
WESTERN BLOT
PCa cells were cultured in RPMI 1640 with 10% FBS and 1% P/S.
Whole cell lysates were prepared from cells, separated on 4–20%
Tris–Glycine gels and transferred to PVDF membranes. The
membranes were incubated with 5% milk for 1 h and incubated
with primary antibodies overnight at 4°C. Primary antibodies used
were as follows: p-CHK2 (1:1,000 dilution, cat. 2197, Cell Signaling),
CHK2 (1:1,000 dilution, cat. 2662, Cell Signaling), Cyclin B1 (1:1,000
dilution, cat. 4138, Cell Signaling), Cyclin D1 (1:1,000 dilution, cat.
sc-753, Santa Cruz, Santa Cruz, CA), CDK4 (1:1,000 dilution,
cat.12790, Cell Signaling), p27 (1:1,000 dilution, cat. 3686, Cell
Signaling), p21 (1:1,000 dilution, cat. 2947, Cell Signaling),
p-CDC25A (1:1,000 dilution, cat. sc-101655, Santa Cruz), CDC25A
(1:1,000 dilution, cat. 3652, Cell Signaling), Cyclin E1 (1:1,000
dilution, cat. sc-481, Santa Cruz), and CDK2 (1:1,000 dilution,
1:1,000 dilution, cat. sc-163, Santa Cruz,), Caspase-3 (1:1,000
dilution, cat. 9662, Cell Signaling), and PARP (1:1,000 dilution, cat.
9542, Cell Signaling). Blots were incubated with peroxidase-coupled
anti-rabbit IgG secondary antibody (cat. 7074, 1:2,000 dilution, Cell
Signaling) for 1 h, and protein expression was detected with
SuperSignal West Dura Chemiluminescent Substrate (cat. Prod
34075, Thermo Scientific, Rockford, IL). Membranes were reprobed
with monoclonal anti-b-actin antibody (1:1,000 dilution; cat. 4970,
Cell Signaling) to control for equal loading.
STATISTICAL ANALYSES
Results are presented as mean standard deviation (s.d.). Signifi-
cance of the difference between two measurements was determined
by unpaired Student0s t-test, and multiple comparisons were
evaluated by the Newman–Keuls multiple comparison test. Values
of P< 0.05 were considered significant.
RESULTS
GAS6 EXPRESSED BY OSTEOBLASTS IN BONE MARROW, WHICH
INHIBITS PCA CELL PROLIFERATION AND EXPRESSION OF CELL
CYCLE MARKERS
We examined the extent to which GAS6 expressed by osteoblasts in
the bone marrow of the long bones of wild-type (GAS6þ/þ) mice
and GAS6 deficient (GAS6/) mice. GAS6 was expressed by
osteoblasts in the marrow of GAS6þ/þmice, but not in the marrow
ofGAS6/mice (Fig. 1A). GAS6 protein levels in the marrow were
also examined. GAS6 protein levels were significantly greater in the
marrow of the GAS6þ/þ versus GAS6/ mice (Fig. 1B). Next, to
test the effects of GAS6 on PCa cell proliferation, proliferation assays
were performed along with gene expression profiling assays for
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cell cycle markers. GAS6 inhibited PCa cell proliferation in a
dose-dependent manner in vitro (Fig. 1C). Levels of mRNA for PLK1
and STK15, indicative of cells in G2/M phase were dramatically
decreased in the PCa cells in response to GAS6 (Fig. 1D and E). These
findings suggest that GAS6 expressed by osteoblasts in bonemarrow
inhibits PCa proliferation.
GAS6 INDUCES G1 CELL CYCLE ARREST IN PCA CELLS IN RESPONSE
TO DOCETAXEL CHEMOTHERAPY
Previously, we demonstrated that GAS6 secreted from osteoblasts
plays a critical role in establishing PCa cell dormancy [Shiozawa et al.,
2010]. Here, we further explored howGAS6 regulates the cell cycle in
PCa cells. For these investigations, the cell-cycle specific Fucci-
Fig. 1. GAS6 expressed by osteoblasts in bone marrow, which inhibits PCa cell proliferation and the expression of cell cycle markers. (A) GAS6 expression by osteoblasts (red,
white arrows) in the bone marrow of the long bones of GAS6 expressing wild-type (GAS6þ/þ) mice and GAS6 deficient GAS6 knockout (GAS6/) mice as detected by
immunofluorescence staining. Blue, DAPI nuclear stain. Bar¼ 20mm. (B) Secretion levels of GAS6 protein in themarrowfluid of the GAS6þ/þ and GAS6/mice as detected by
ELISA. (C) The proliferation assays in PCa cells were performed by XTT. Denotes P< 0.05 between vehicle versus GAS6 treated PCa cells by Student0s t-test. mRNA expression
levels of (D) PLK1 and (E) STK15 were measured as qPCR. Data in Figure 1B–E are representative of mean with s.d. (Student0s t-test).
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vectors were employed in PC3 cells and Fucci expression was used to
isolate cells at different stages of the cell cycle [Sakaue-Sawano et al.,
2008] by examining FACSprofiles of cells inG1, S, andG2/M (Fig. 2A).
In standard cultures, we found that 2mg/ml of GAS6 increased the
percentage of cells in G1 phase significantly at 48 and 72h (Fig. 2B).
We next examined the duration of cell cycle phase bys live-cell
imaging of GAS6 treated Fucci-PC3 cells for 24h.
We found that GAS6 treated Fucci-PC3 remained in the G1 phase
for 20.8 h 15min versus 9.1 h for vehicle treated cells (Fig. 2C and D).
The cell cycle monitoring was next performed for docetaxel treated
cells with the presence or absence of GAS6. More G1 arrested cells
were identified after docetaxel and GAS6 treatments at 24 and 48 h
(Fig. 2E). In addition, cell cycle monitoring was performed in
cocultured Fucci-PC3 cells with GAS6 expressing wild-type
Fig. 2. GAS6 induces G1 cell cycle arrest in PCa cells during docetaxel chemotherapy. (A) A flow profile of the cell cycle status; G1, S, and G2/M in Fucci-PC3 cells. (B) % G1 cells
in Fucci-PC3 cells following treatment of GAS6 (0–2mg/ml) in standard culture conditions for 72 h. (C) The living cell imaging of Fucci-PC3 (red arrows) following GAS6 (2mg/
ml) treatment by video for 24 h with 15min interval by Deltavision Elite Microscope. Bar¼ 20mm. (D) Quantification of G1 duration in the single cell from Figure 2C (n¼ 20/
group). (E)% G1 cells in Fucci-PC3 cell culture following the treatment of docetaxel with the presence or absence of GAS6. (F)%G1 cells in cocultured Fucci-PC3 cells with GAS6
expressing wild-type osteoblasts (GAS6þ/þ OB) or GAS6 deficient osteoblasts (GAS/ OB) following the treatment of docetaxel. Data in Figure 2B, D–F are representative of
mean with s.d. (Student0s t-test).
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osteoblasts (GAS6þ/þ OB) or GAS6 deficient osteoblasts
(GAS/ OB) following treatment with docetaxel. More G1 arrested
cells were found in coculture with wild-type osteoblasts
(GAS6þ/þ OB) compared to GAS6 deficient osteoblasts
(GAS/ OB) in both vehicle- and docetaxel-treated conditions
(Fig. 2F). Collectively, the data suggest GAS6 expressed by
osteoblasts may regulate the growth arrest during docetaxel
chemotherapy in bone marrow microenvironment.
GAS6 UPREGULATES G1 CELL CYCLE ARREST SIGNALS AND
DOWNREGULATES S PHASE ENTRY SIGNALS DURING DOCETAXEL
CHEMOTHERAPY IN PCA CELLS
Docetaxel is known to downregulate genes associated with cell
proliferation, while upregulating genes associated with cell cycle
arrest and induction of apoptosis [Li et al., 2004]. Therefore, we
examined the protein expression of several core cell cycle regulators
including cyclins, CDKs, CDK inhibitors, and cell cycle checkpoint
regulators byWestern blot in PCa cell cultures treated with docetaxel
and/or GAS6. We found that Cyclin B1 (G2/M marker) and CDC25A,
Cyclin E1, CDK2 (S phase entry regulators) were downregulated,
while p27, p21, Cyclin D1, and CDK4 (associated with expression at
G0/G1) were upregulated in GAS6 treated PCa cells (Fig. 3A and B).
These expression changes were further accentuated in PCa cells
treated with docetaxel and GAS6. These data suggest that GAS6
promotes G1 cell cycle arrest and a delayed entry into S phase.
GAS6 EXPRESSED BY OSTEOBLASTS CONTRIBUTES TO THE
PROTECTION OF PCA CELLS FROM DOCETAXEL-INDUCED
APOPTOSIS
PCa cells are known to develop resistance to chemotherapies,
particularly in the marrow. To explore whether GAS6 plays a role
in this process, we first examined the percentage of apoptotic cells
following treatment with docetaxel and/or GAS6 by Annexin V
staining. As expected, more PCa cells underwent apoptosis following
docetaxel treatment compared to vehicle treatment (Fig. 4A and B).
However, fewer PCa cells underwent apoptosis in the presence of
GAS6 for both vehicle and docetaxel treatment (Fig. 4A and B).
Additionally, we performed an apoptosis assay on cocultures of PC3
cells with GAS6þ/þ OB or GAS/ OB following docetaxel
treatment. Fewer apoptotic cells were identified when PCa cells
were cocultured with GAS6þ/þ OB versus GAS/ OBs in both
vehicle and docetaxel treatment (Fig. 4C and D). To validate these in
vitro studies, nextweperformedTUNEL stainingon tumors grown ina
GAS6þ/þ or GAS6/ bone environment (e.g., vossicles) as from
previous studies [Jung et al., 2012]. Fewer apoptotic tumor cells were
found in the tumors established by PC3 cells within GAS6þ/þ
vossicles compared with GAS6/ vossicles (Fig. 4E and F). Finally,
we examined the extent to which GAS6 regulates docetaxel-induced
apoptosis signaling in PCa cells. For these investigations, Caspase-3
and PARP levels in PCa cells following treatment with docetaxel and/
or GAS6 were examined by Western blots. We found that docetaxel
Fig. 3. GAS6 regulates signals associated cell cycle during docetaxel chemotherapy in PCa cells. Examination of expression of the checkpoint and cell cycle related proteins; p-
CHK2, CHK2 (checkpoint), Cyclin B1 (G2/Mmarker), Cyclin D1, CDK4, p27, and p21 (G0/G1marker), and CDC25A, Cyclin E1, CDK2 (S phase entry marker) in the cultures of (A) PC3
cells and (B) DU145 cells following docetaxel treatment with the presence or absence of GAS6 by Western blots.
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Fig. 4. GAS6 expressed by osteoblasts contributes to the protection of PCa cells from docetaxel-induced apoptosis. Examination of % apoptosis in (A) PC3 and (B) DU145 cells
following the docetaxel treatment with the presence or absence of GAS6 by FACS analysis using Annexin V staining. Examination of% apoptosis in (C) PC3 and (D) DU145 cells in
cocultured PC3 cells with GAS6þ/þ OB or GAS/ OB following the treatment of docetaxel. (E) Apoptotic tumor cells (red, white arrows) in the tumor-established PC3 cells
within GAS6þ/þ vossicles or GAS6/ vossicles as evaluated by TUNEL staining. Blue, DAPI nuclear stain. Bar¼ 50mm. (F) Quantification of % apoptotic cells from Figure 4E.
Docetaxel-induced apoptotic signaling, Caspases-3 and PARP in (G) PC3 cells and (H) DU145 cells following the treatment of docetaxel with the presence or absence of GAS6
were evaluated by Western blots. Data in Figure 4A–D, F are representative of mean with s.d. (Student0s t-test).
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induces significant levels of Caspase-3 and PARP cleavages in PCa
cells. Importantly, GAS6 protected caspase-3 and PARP from
cleavage in the PCa cells (Fig. 4G and H). Collectively, these data
suggest that GAS6 expressed by osteoblasts in bone marrow plays a
significant role in the regulation of PCa cell survival during docetaxel
chemotherapy.
DISCUSSION
Recent studies suggest that signals from the bone marrow
microenvironment protect PCa cells from chemotherapy. Here, we
demonstrate that GAS6 expressed by osteoblasts regulates cell cycle
and apoptosis of PCa cells during chemotherapy.We found that GAS6
significantly increased G1 arrested PCa cells by signals associating
with G1 cell arrest and S phase delay. Furthermore, we found that
GAS6 contributes to the protection of PCa cells from docetaxel-
induced apoptosis andaGAS6-expressing bone environment protects
PCa cell apoptosis within the primary tumors in vivo. Finally, we
found that GAS6 promotes survival by preventing the activation of
docetaxel-induced apoptotic signaling through, Caspase-3, and
PARP. Our results suggest that GAS6 expressed by osteoblasts in
the bone marrow plays a significant role in regulation of PCa cell
survival during chemotherapy.
PCa frequently takes more than 5 years to progress to lethal
metastatic disease or biochemical recurrence after curative surgery
or radiation therapy [Amling et al., 2000; Morgan et al., 2009;
Roberts andHan, 2009] indicating that DTCsmay enter into a state of
cellular dormancy for long periods within metastatic sites [Quesnel,
2008; Yumoto et al., 2014]. Yet how DTC cells become dormant,
acquire resistance to anticancer drugs, and ultimately cause tumor
recurrence/metastatic relapse remain critical questions. Previously,
we demonstrated that GAS6 secreted from osteoblasts plays a critical
role in establishing PCa cellular dormancy [Shiozawa et al., 2010].
Here, we further demonstrate the mechanism by which GAS6
regulates cell cycle of PCa cells in response to chemotherapy. GAS6
increases the number of G1 arrested cells and the duration of arrest
by downregulation of Cyclin B1 (G2/M phase), CDC25A, Cyclin E1,
and CDK2 (S phase entry) and upregulation of the cell cycle
inhibitors p27, p21 in PCa cells during docetaxel chemotherapy.
Intensive studies have identifiedmechanisms of targetmolecules or
signals associated with the anti-proliferative effects and anti-
tumorigenic activities for thePCa treatment. Docetaxel-chemotherapy
targets proliferating cancer cells, which are associated with the up
regulation of core cell cycle regulators including cyclins, CDKs, and
down regulation of CDK inhibitors [EL-Deiry et al., 1995; Kawamata
et al., 1995; Nilsson and Hoffmann, 2000; Erlanson and Landberg,
2001; Poggioli et al., 2001; Yoo et al., 2002; Li et al., 2004; Roy et al.,
2008; Chiu et al., 2009]. Double knockdown of the cyclin-dependent
kinase inhibitor 1A (p21) and the cyclin-dependent kinase inhibitor 1B
(p27) in DU145 cells results in a higher tumor growth rate than the
comparable growth of either p21 or p27 knockdown [Roy et al., 2008].
Another important cell cycle regulator, the phosphatase CDC25A,
which activates CDK2 by removal of an inhibitory phosphate, is highly
expressed during S phase entry of the cell cycle in many cancers
[Busino et al., 2004; Lavecchia et al., 2009]. CDC25A has oncogenic
properties, is highly expressed in human PCa, and its expression level
correlates with high Gleason scores and metastatic PCa [Chiu et al.,
2009]. The expression of CDC25A in PCa cells suppresses PSA
expression and functions as anAR corepressor, suggesting that it may
also be a possible anticancer target [Li et al., 2004; Chiu et al., 2009].
Docetaxel continues to be an effective agent for growth inhibition and
induction of apoptosis in part by the upregulation of growth arrest
signals during treatment. Yet these actions also lead to the generation
of cell cycle arrest signals, which induce cellular dormancy and
ultimately increase drug-resistance. Here, we show that in docetaxel-
chemotherapy treated PCa cells, GAS6 further downregulates cell
cycle regulators including Cyclin B1, CDC25A, Cyclin E1, and CDK2
and upregulates cell cycle inhibitors including p27 and p21. Taken
together, GAS6 promotes the induction of drug resistance-inducing in
docetaxel-treated PCa cells. Future cancer therapeutic studies will be
required to identify selective agents capable of inducing cancer cell
apoptosis without inducing dormancy within the context of these
complex microenvironmental cues.
Theabilityofdocetaxel topromote cancer cell apoptosis is dependent
on its function in cell death signaling [Jin and El-Deiry, 2005]. During
the G2/M phase arrest of cancer cells, docetaxel binds to microtubules
with high affinity, activating JNK signaling causingB-cell lymphoma2
(Bcl-2) phosphorylation, thereby promoting a cascade of events that
ultimately leads to apoptotic cell death [Haldar and Basu, 1997].
Increased JNK signaling also increases dephosphorylation of Bad,
which associates with Bcl-2, releasing Bcl-2 from Bax. Unbound Bax
translocates to the inner mitochondrial membrane forming Bax/Bax
pores, allowing release of cytochrome c and activation of caspases
leading to apoptosis [Wolter et al., 1997]. Reduction of multidrug
resistance-associated protein-1 (MRP-1) by pre-treatment of 1,25-
dihydroxy vitamin D3 (1,25-VD) enhanced the docetaxel antitumor
activity through Bcl-2 signaling pathway in PC3 cells [Tinga et al.,
2007]. Docetaxel is also able to induce apoptosis through different
caspase families in PCa cells; Caspase-3 and Caspase-7 in LNCaP and
TSU-Pr1 cells versus Caspase-8 in PC3 cells [Marcelli et al., 1999;
Muenchen et al., 2001]. Furthermore, Docetaxel-induced apoptosis has
also been associated with the increases of Survivin, GADD45A, Fas/
Apo-1, and FOXO3A in PCa cells [Li et al., 2004]. Apoptosis is guided by
a complex series of cellular events and initiation of these events is
tightly regulated by the balance of cell death and survival signals. The
balance of these signaling mediators is not yet fully understood, but is
essential in understanding mechanisms that govern cell fate such as
apoptosis and cancer cell resistance.
Just as the docetaxel-inducing apoptotic signaling pathways have
been elucidated, there is increasing evidence that docetaxel can confer
resistance to cancer cells. For example, PIAS1 is a crucial survival
factor, which was significantly increased in docetaxel resistant cells
and in tissue of patients after docetaxel chemotherapy. Down-
regulation of PIAS1 results in increased apoptosis, suggesting the
importance of PIAS1 in maintaining cell survival [Puhr et al., 2014].
Moreover, GAS6 induces activation of AKT/PKB leading to the
phosphorylation of Bad as well as activation of ERK, JNK/SAPK, and
p38 MAPK in serum starved NIH3T3 cells [Goruppi et al., 1999]. In
addition, GAS6 secreted by osteoblasts rapidly induces the phos-
phorylation of ERK in PC3 cells in standard culture conditions, which
provides evidence that GAS6 can promote PCa cell survival
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[Shiozawa et al., 2010]. However, the balance between cell survival
signals andapoptotic signals in cell fate remainspoorlyunderstood. In
this investigation, we further demonstrated that docetaxel signifi-
cantly increases the apoptotic signals, cleaved Caspase-3 and PARP in
PCa cells, while GAS6 protected PCa cells from Caspase-3 and PARP
cleavages. These data suggest that GAS6may be a critical molecule in
suppressing the activation of key apoptotic signaling mediators, thus
promoting cell survival. Therefore, targeting GAS6 or GAS6 signaling
during cancer therapy for metastatic diseases may be helpful in
elimination of quiescent PCa DTCs, as well.
In summary, this work provides evidence that supports a crucial
role for GAS6 in PCa cell survival during chemotherapy within the
bone marrow microenvironment (Fig. 5). Importantly, this work
contributes to the understanding of dormancy signals that facilitate
chemotherapeutic resistance in PCa cells, which may have important
implications for optimizing therapeutic strategies against metastatic
disease and tumor recurrence.
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